<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754442</url>
  </required_header>
  <id_info>
    <org_study_id>H-28679</org_study_id>
    <secondary_id>H-28679</secondary_id>
    <nct_id>NCT00754442</nct_id>
  </id_info>
  <brief_title>Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism</brief_title>
  <acronym>1hydroxylase</acronym>
  <official_title>Clinical and Molecular Characterization of Suspected Partial 25-hydroxyvitamin D-1-alpha-hydroxylase Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a reduction in the enzyme 1-hydroxylase, which
      activates Vitamin D, is the cause of overactivity of the parathyroid glands (called secondary
      hyperparathyroidism - normal blood calcium and elevated parathyroid hormone) in a selected
      group of young patients with normal kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D, an essential nutrient, is produced by the skin after sunlight shines on it.
      Vitamin D must then be activated by both the liver and the kidneys to perform its function of
      maintaining strong bones and helping to prevent heart disease, infection, diabetes and
      cancer. Reduced kidney activation of Vitamin D occurs with advanced age and with all kidney
      diseases. We have identified a small group of patients who appear to have reduced ability of
      the kidneys to activate vitamin D, even though they are young and do not have chronic kidney
      disease. In these patients, we are comparing the ability of their kidneys to activate Vitamin
      D to that of healthy controls. To stimulate the kidneys to activate Vitamin D, we are giving
      parathyroid hormone intravenously over 8 hours and collecting blood and urine at baseline, 4
      and 8 hours. This type of parathyroid infusion does not cause side effects. The gene that
      controls this activation is also being studied (by a simple blood test) to look for
      abnormalities. We are now actively recruiting healthy controls for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours</measure>
    <time_frame>baseline, 4 and 8 hours after start of infusion</time_frame>
    <description>1,25-D was measured at baseline, 4 and 8 hours after PTH infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Patients With Mutations in CYP27B1</measure>
    <time_frame>blood samples taken at baseline and sequenced over several days</time_frame>
    <description>CYP27B1 gene (the gene for 25-hydroxyvitamin D-1-alpha hydroxylase) was sequenced for all in patient group and compared with published control data</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Secondary Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>teriparatide control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control subject</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with secondary hyperparathyroidism</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both &quot;patients&quot; and &quot;controls&quot;</description>
    <arm_group_label>teriparatide control</arm_group_label>
    <arm_group_label>Teriparatide Patient</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian female

          -  Age 40-59 years

          -  Serum creatinine &lt; 1.3 and estimated glomerular filtration rate (GRF) &gt; 60

          -  Serum calcium in the normal range (for U Md lab 8.6-10 mg/dl)

          -  Parathyroid hormone in the normal range (for U Md lab 12-54 pg/ml)

          -  Normal 25-hydroxyvitamin D level (30 ng/ml or higher)

          -  For women of childbearing age, non-pregnant (based on negative urine pregnancy test on
             the morning of the teriparatide infusion)

        Exclusion Criteria:

          -  Non-caucasian

          -  Age under 40 and over 59 years

          -  Male

          -  Serum creatinine over 1.3 or estimated glomerular filtration rate (GFR) &lt; 60

          -  Abnormal serum calcium (for U Md lab, below 8.6 or above 10 mg/dl)

          -  Abnormal parathyroid hormone (for U Md lab, above 65 or below 12 pg/ml)

          -  For women of childbearing age, non-pregnant (based on urine pregnancy test on the
             morning of the teriparatide infusion)

          -  History of bone radiation

          -  History of Paget disease of bone

          -  History of bone malignancy or metastases

          -  History of allergy or sensitivity to Forteo
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth A Streeten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Endocrinology, University of Maryland School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland School of Medicine Division of Endocrinology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Streeten EA, Rogstad AS, Flammer KM, Zarbalian K, Ryan K, Horwitz M, Holick MF, Shelton J. Reduced parathyroid hormone-stimulated 1,25-dihydroxyvitamin d production in vitamin d sufficient postmenoposual women with low bone mass and idiopathic secondary hyperparathyroidism. Endocr Pract. 2013 Jan-Feb;19(1):91-9. doi: 10.4158/EP12151.OR.</citation>
    <PMID>23186957</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <results_first_submitted>January 17, 2013</results_first_submitted>
  <results_first_submitted_qc>May 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 14, 2014</results_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Elizabeth Streeten</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>hyperparathyroidism</keyword>
  <keyword>parathyroid</keyword>
  <keyword>vitamin D</keyword>
  <keyword>vitamin D deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Secondary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All in the &quot;patient&quot; group were recruited from the Metabolic Bone Clinic at U Md, except one, who was recruited from prior participation in the Amish Family Osteoporosis Study, recruited from 3/15/07-11/14/08</recruitment_details>
      <pre_assignment_details>Of 11 &quot;controls&quot; enrolled, 6 completed the study and 5 dropped out because they didn't want to do the parathyroid hormone (PTH) infusion. Of 9 &quot;patients&quot; recruited, 6 completed the study. The others were excluded after their screening labs showed that their renal function was below the inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Controls</title>
          <description>controls with normal PTH</description>
        </group>
        <group group_id="P2">
          <title>Patient Group</title>
          <description>patients with secondary hyperparathyroidism</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11">controls 11</participants>
                <participants group_id="P2" count="9">patients 9</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Controls</title>
          <description>controls with normal PTH</description>
        </group>
        <group group_id="B2">
          <title>Patient Group</title>
          <description>patients with secondary hyperparathyroidism</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="4.4"/>
                    <measurement group_id="B2" value="53.0" spread="2.5"/>
                    <measurement group_id="B3" value="52.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours</title>
        <description>1,25-D was measured at baseline, 4 and 8 hours after PTH infusion</description>
        <time_frame>baseline, 4 and 8 hours after start of infusion</time_frame>
        <population>The final analysis was made on participants with glomerular filtration rate (GFR) of 70 and above since &lt;70, 1,25-D production decreases. After study completion, it was noted that one participant in each group (patient and control) had GFR&lt;70 so these two participants were excluded from final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>&quot;patients&quot; with secondary hyperparathyroidism</description>
          </group>
          <group group_id="O2">
            <title>Controls</title>
            <description>Controls without secondary hyperparathyroidism</description>
          </group>
        </group_list>
        <measure>
          <title>The Level of Activated Vitamin D (1,25-dihydroxyvitamin D) After Parathyroid Hormone Infusion at Baseline, 4 and 8 Hours</title>
          <description>1,25-D was measured at baseline, 4 and 8 hours after PTH infusion</description>
          <population>The final analysis was made on participants with glomerular filtration rate (GFR) of 70 and above since &lt;70, 1,25-D production decreases. After study completion, it was noted that one participant in each group (patient and control) had GFR&lt;70 so these two participants were excluded from final analysis.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" spread="5.6"/>
                    <measurement group_id="O2" value="46.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" spread="6.0"/>
                    <measurement group_id="O2" value="58.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="9.2"/>
                    <measurement group_id="O2" value="105" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no statistical difference between patients and controls at baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1</p_value>
            <p_value_desc>see above</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>95%</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no statistical difference between patients and controls at 4 hours</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no statistical difference between patients and controls at 8 hrs</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Patients With Mutations in CYP27B1</title>
        <description>CYP27B1 gene (the gene for 25-hydroxyvitamin D-1-alpha hydroxylase) was sequenced for all in patient group and compared with published control data</description>
        <time_frame>blood samples taken at baseline and sequenced over several days</time_frame>
        <population>All patients were sequenced and compared to published control data. Controls were not sequenced for cost reasons</population>
        <group_list>
          <group group_id="O1">
            <title>Patients</title>
            <description>patients with idiopathic secondary hyperparathyroidism</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients With Mutations in CYP27B1</title>
          <description>CYP27B1 gene (the gene for 25-hydroxyvitamin D-1-alpha hydroxylase) was sequenced for all in patient group and compared with published control data</description>
          <population>All patients were sequenced and compared to published control data. Controls were not sequenced for cost reasons</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During PTH infusion, 2 participants, one in patient and one in control groups had one episode of vomiting each.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Controls</title>
          <description>controls with normal PTH</description>
        </group>
        <group group_id="E2">
          <title>Patient Group</title>
          <description>patients with secondary hyperparathyroidism</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <description>One patient and one control each had one episode of vomiting during the PTH infusion. Both continued the full 8 hrs of infusion</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elizabeth A Streeten, MD</name_or_title>
      <organization>University of Maryland School of Medicine</organization>
      <phone>410-328-6219</phone>
      <email>estreete@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

